Biomed Caucus Members Express Cautious Optimism On Prospect For Boost In Federal Research Funds

University department chairpersons have been pushing to see dollar support for NIH double in the near future Five billion dollars is not enough, according to a group pushing for the federal government to pump more money into the basic biomedical research funded by the National Institutes of Health. And with Bill Clinton now in the White House, members of the group--the National Caucus of Basic Biomedical Science Chairs-- say they are very optimistic about achieving their goal. Composed of 2

Written byRon Kaufman
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Composed of 21 biomedical department chairpersons from 19 different United States universities, the caucus convenes annually at George Washington University in Washington, D.C., to try to educate lawmakers about the importance of increasing funding for the basic biomedical sciences and to lobby for more support. They say ripe fields for investment are molecular and cell biology, molecular genetics, immunology, and structural biology.

In an editorial published last October in the FASEB Journal (6:3133-4, 1992), the caucus proclaimed that the level of NIH funding for basic research cannot be "the previous small and insufficient annual increments that were based largely on matching inflation," but rather "will require doubling current spending for biomedical research over the next few years."

Though the caucus has not yet established any dialogue with the Clinton administration, many of the members are hopeful that funding will increase under the new president. "I think that it's not likely ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies